ISSN : 0975-9492


Open Access

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information:
verify here.


Title : Formulation and In-vitro Evaluation of Gemifloxacine Orodispersible Tablet
Authors : Mohammed L. Hamza, Laith H. Samein, Muyad A .Shehab
Keywords : Gemifloxacin, orodispersible, disintegration, direct compression
Issue Date : February 2015
Abstract :
Gemifloxacin is a fluoroquinolone antibacterial with actions and uses similar to those of ciprofloxacin. It is granted orally, as the mesylate, for the treatment of community acquired pneumonia and acute bacterial exacerbations of chronic bronchitis .Various super disintegrants were used in this study including croscarmellose sodium, sodium starch glycolate and crospovidone. The formulas were measured for flow properties, tablet hardness, friability, content uniformity, wetting time, in vitro disintegration time (DT), and drug release profiles. Crospovidone (CP) showed the shortest DT (*p<0.05*) among other superdisintegrants and fast drug release. The disintegration time of the gemifloxacin orodispersible tablet was decreased to a significant level upon addition of glycine (disintegration enhancer). It is worthwhile to mention that the addition of chitin (porosity enhancer) has a dramatic effect on the disintegration time of the prepared gemifloxacin orodispersible tablet. The formula containing 15% of CP and 8% of chitin (GF15) had the shortest DT (24.6sec.), superior drug release profile [the time required for 80% of the drug to be released (t80%) and percent drug released in 2 min (D2min) were 6.1 min. And 55.3% respectively] so it was selected as the best formula. The drug-excipient compatibility study indicated that no interaction of the drug occurred with the components of the formula, and the accelerated stability study showed no significant changes (*p<0.05*) in tablet properties. The overall results suggested that the prepared formula of gemifloxacin (GF15) could be utilized as a new dosage form for the oral administration.
Page(s) : 386-393
ISSN : 0975-9492
Source : Vol. 6, No.2